Gilead Reports Officer Comp/Director Changes on Feb 1

TL;DR

**Gilead filed an 8-K on Feb 2nd, signaling executive compensation or leadership changes from Feb 1st.**

AI Summary

Gilead Sciences, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on February 1, 2024. This filing indicates a change in compensatory arrangements for certain officers, as well as potential departures or elections of directors or officers. While specific names and dollar amounts are not detailed in this summary filing, it signals potential shifts in executive compensation or leadership, which could impact the company's strategic direction and financial performance, making it relevant for current and prospective shareholders.

Why It Matters

Changes in executive compensation or leadership can signal strategic shifts or impact investor confidence, directly affecting the stock's perceived value.

Risk Assessment

Risk Level: medium — Without specific details on the changes, there's uncertainty regarding the impact on company stability and future performance.

Analyst Insight

Investors should monitor future Gilead filings or press releases for specific details on the reported compensatory arrangements and personnel changes to assess their potential impact on the company's strategy and financial outlook.

Key Numbers

• $0.001 — Common Stock par value per share (This is the nominal value of each share of Gilead's common stock.)

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — the registrant filing the 8-K
• February 1, 2024 (date) — date of the earliest event reported in the 8-K
• February 2, 2024 (date) — date the 8-K was filed
• $0.001 (dollar_amount) — par value per share of Common Stock
• The Nasdaq Global Select Market (exchange) — where Gilead's Common Stock is registered

Forward-Looking Statements

• Gilead will provide more specific details regarding the compensatory arrangements or personnel changes in a future filing or press release. (GILEAD SCIENCES, INC.) — medium confidence, target: Q1 2024

FAQ

From the Filing

0001104659-24-010051.txt : 20240202 0001104659-24-010051.hdr.sgml : 20240202 20240202162027 ACCESSION NUMBER: 0001104659-24-010051 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240201 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24591753 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm244922d1_8k.htm FORM 8-K false 0000882095 CA 0000882095 2024-02-01 2024-02-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 1, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)       Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)   333 LAKESIDE DRIVE , FOSTER CITY , CALIFORNIA (Address of principal executive offices)   94404 (Zip Code)   ( 650 ) 574-3000 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).    Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers   (d) Appointment of a Director.   On February 1, 2024, at a meeting of the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”), the Board increased the size of the Board from nine directors to ten directors and elected Ted